Antibodies against LAG-3, TIM-3, TIGIT, CD47, and B7-H3 are the most advanced IC blockade drugs and may be approved for the treatment of specific tumor types in the near future, depending on the results of the trials. The gene discussed is CD47; the disease is neoplasm.